Objectives: Pegfilgrastim is a granulocyte colony-stimulating factor (G-CSF) used as primary prophylaxis in patients receiving myelosuppressive chemotherapy regimens that have greater than 20% risk of developing febrile neutropenia (FN). Historically, pegfilgrastim has been administered 24 to 72 hours after chemotherapy, necessitating a return to clinic to receive the provider-administered injection. An alternative option is the pegfilgrastim on-body injector (OBI). With the OBI device, patients have their pegfilgrastim administered 27 hours after receiving chemotherapy while remaining at home, avoiding an additional clinic appointment. Concerns with pegfilgrastim OBI include lack of experience with the device in both the patient and provider, device-related failures, and the success of delivery. This study evaluates pegfilgrastim OBI failure rates through associated patient outcomes among cancer patients receiving chemotherapy requiring G-CSF. Methods: A retrospective electronic chart review was conducted of adult patients with cancer who received chemotherapy and pegfilgrastim OBI from July 1, 2016, to July 31, 2018. The primary objective of this study was the incidence of FN in patients receiving pegfilgrastim OBI. Results: There were no reported cases of hospitalization due to FN in patients who received pegfilgrastim OBI. Dose delays and dosage modifications were not observed in our review. The OBI device failure rate was found to be low (1.92%). Conclusion: The low device failure rate from this study suggests that the OBI is a viable option for administration of pegfilgrastim in patients receiving chemotherapy requiring G-CSF.
Objectives: Pegfilgrastim is a granulocyte colony-stimulating factor (G-CSF) used as primary prophylaxis in patients receiving myelosuppressive chemotherapy regimens that have greater than 20% risk of developing febrile neutropenia (FN). Historically, pegfilgrastim has been administered 24 to 72 hours after chemotherapy, necessitating a return to clinic to receive the provider-administered injection. An alternative option is the pegfilgrastim on-body injector (OBI). With the OBI device, patients have their pegfilgrastim administered 27 hours after receiving chemotherapy while remaining at home, avoiding an additional clinic appointment. Concerns with pegfilgrastim OBI include lack of experience with the device in both the patient and provider, device-related failures, and the success of delivery. This study evaluates pegfilgrastim OBI failure rates through associated patient outcomes among cancer patients receiving chemotherapy requiring G-CSF. Methods: A retrospective electronic chart review was conducted of adult patients with cancer who received chemotherapy and pegfilgrastim OBI from July 1, 2016, to July 31, 2018. The primary objective of this study was the incidence of FN in patients receiving pegfilgrastim OBI. Results: There were no reported cases of hospitalization due to FN in patients who received pegfilgrastim OBI. Dose delays and dosage modifications were not observed in our review. The OBI device failure rate was found to be low (1.92%). Conclusion: The low device failure rate from this study suggests that the OBI is a viable option for administration of pegfilgrastim in patients receiving chemotherapy requiring G-CSF.
Authors: A Brett Hauber; Brennan Mange; Mark A Price; Daniel Wolin; Mark Bensink; James A Kaye; David Chandler Journal: Support Care Cancer Date: 2017-08-07 Impact factor: 3.603
Authors: Jeffrey Crawford; Pamela Sue Becker; James O Armitage; Douglas W Blayney; Julio Chavez; Peter Curtin; Shira Dinner; Thomas Fynan; Ivana Gojo; Elizabeth A Griffiths; Shannon Hough; Dwight D Kloth; David J Kuter; Gary H Lyman; Mary Mably; Sudipto Mukherjee; Shiven Patel; Lia E Perez; Adam Poust; Raajit Rampal; Vivek Roy; Hope S Rugo; Ayman A Saad; Lee S Schwartzberg; Sepideh Shayani; Mahsa Talbott; Saroj Vadhan-Raj; Sumithira Vasu; Martha Wadleigh; Peter Westervelt; Jennifer L Burns; Lenora Pluchino Journal: J Natl Compr Canc Netw Date: 2017-12 Impact factor: 11.908
Authors: Randy A Taplitz; Erin B Kennedy; Eric J Bow; Jennie Crews; Charise Gleason; Douglas K Hawley; Amelia A Langston; Loretta J Nastoupil; Michelle Rajotte; Kenneth Rolston; Lynne Strasfeld; Christopher R Flowers Journal: J Clin Oncol Date: 2018-02-20 Impact factor: 44.544
Authors: Rajeshree S Joshi; Ogo I Egbuna; Alex S Cairns; Michael J Friedman; Bassam Abosaleem; Maureen T Reiner; Phuong Khanh Morrow Journal: Curr Med Res Opin Date: 2016-12-02 Impact factor: 2.580
Authors: Eva Culakova; Ramya Thota; Marek S Poniewierski; Nicole M Kuderer; Adane F Wogu; David C Dale; Jeffrey Crawford; Gary H Lyman Journal: Cancer Med Date: 2014-02-17 Impact factor: 4.452
Authors: Reshma L Mahtani; Rajesh Belani; Jeffrey Crawford; David Dale; Lucy DeCosta; Prasad L Gawade; Chanh Huynh; Tatiana Lawrence; Sandra Lewis; William W MacLaughlin; Mohit Narang; Robert Rifkin Journal: Support Care Cancer Date: 2022-04-14 Impact factor: 3.603